Cargando…
Tocilizumab-Induced Acute Liver Injury in Adult Onset Still's Disease
Background. Tocilizumab, a monoclonal humanized anti-IL-6 receptor antibody, is used in treatment of refractory adult onset Still's disease (AOSD). Mild to moderate liver enzyme elevation is a well-known side effect, but severe liver injury has only been reported in 3 cases in the literature. C...
Autores principales: | Drepper, Michael, Rubbia-Brandt, Laura, Spahr, Laurent |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4208420/ https://www.ncbi.nlm.nih.gov/pubmed/25374723 http://dx.doi.org/10.1155/2013/964828 |
Ejemplares similares
-
Disulfiram-Induced Acute Liver Injury
por: Ramer, Lucas, et al.
Publicado: (2020) -
Severe Starvation-Induced Hepatocyte Autophagy as a Cause of Acute Liver Injury in Anorexia Nervosa: A Case Report
por: Restellini, S., et al.
Publicado: (2013) -
Adult-onset Still's Disease during Pregnancy Treated with Tocilizumab
por: Imaizumi, Chihiro, et al.
Publicado: (2022) -
Corticosteroid-Induced Liver Injury in Adult-Onset Still’s Disease
por: Lee, Chin-Chi, et al.
Publicado: (2022) -
Autoimmune hepatitis complicated by adult‐onset Still's disease during treatment with tocilizumab: A case report from acute onset to recurrence
por: Uchihara, Daiki, et al.
Publicado: (2023)